BioSpace News Archive

Regeneron Pharmaceuticals announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.

Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.

Companies that have a strong focus on developing drugs that target messenger RNA (mRNA) may be ahead of the curve when it comes to potentially tapping into a lucrative market space.

Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.

Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year.

Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.

Heron Therapeutics said its late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain – a significant point as the nation is in the grip of an opioid epidemic.

In the world of politics and civil rights, the ideas of gender and transgender have been a hot-button issue. But a new study suggests that transgender people may have a genetic disposition that influences their identity.

Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, recently announced the launch of AmyloidIQ, a new and advanced algorithm that quantifies Amyloid scans for use in subject stratification and clinical trials of Alzheimer’s disease therapies.

Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey, with the aim to: increase capacity in existing technologies, like spray drying and grow in new areas of business to support its clients demand.